While all GLP-1 medications may promote some weight loss, three drugs are specifically indicated for chronic weight management: Zepbound (tirzepatide) Wegovy (semaglutide) Saxenda (liraglutide) Multiple clinical trials have found that each of these medications can help people lose 5%-20% or more of their body weight though research suggests that some may be more effective than others
In late 2024, Zealand Pharma initiated a phase 2b randomized dose-finding obesity and T2DM + obesity clinical trial (ZUPREME-1 and ZUPREME-2) which will evaluate petrelintides efficacy and safety in individuals with obesity in a larger population ( N = 480) [116]
Resources Yan Z, Garg SK, Banerjee R
Book your In-Office Appointment/Pick-Up or Shop Online at www.drfortinoweightloss.com for convenient home delivery
Liquid Calories, Alcohol & Mindless Bites Slip Under the Radar Smoothies, lattes, wine, and just a bite snacks digest quickly and rarely trigger the fullness signal semaglutide amplifies
Purpose-built for physicians GLP-1 receptor agonist use for more than 1 year may increase thyroid cancer risk Adults with type 2 diabetes who use a GLP-1 receptor agonist for more than 1 year may have an increased risk for thyroid cancer, according to findings published in Diabetes Care